Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose subcutaneous decitabine combined with compound Huangqi tablets for moderate- to high-risk myelodysplastic syndrome
ChiCTR1900022121Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine and compound Huangqi tablets in myelodysplastic syndrome (MDS), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Started Apr 2019; status: recruiting.
02
Drugs
decitabinecompound Huangqi tablets
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1900022121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022121.